1) A Phase IA/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients with Gleevec-resistant CML in Accelerated Phase or Blast Crisis, Relapsed/Refractory PH+All, and Other Hematologic Malignancies. This study is being conducted in:
- Duarte, CA http://www.centerwatch.com/patient/studies/stu85586.html
2) A Single ARM, Multicenter Phase II Trial of Transplants of HLA-Matched, CD34+Enriched, T Cell Depleted Peripheral Blood Stem Cells Isolated by The CliniMACS System in The Treatment of Patients With AML in First or Second Morphologic Complete Remission. This study is being conducted in:
- Duarte, CA http://www.centerwatch.com/patient/studies/stu85575.html
3) Allogeneic Stem Cell Transplantation with a Novel Conditioning Therapy Using Helical Tomotherapy, Melphalan, and Fludarabine in Acute Myelogenous Leukemia. This study is being conducted in:
- Duarte, CA http://www.centerwatch.com/patient/studies/stu85581.html
4) Blood and Marrow Transplantation: Linking Caregiving and Recovery. This study is being conducted in:
- Duarte, CA http://www.centerwatch.com/patient/studies/stu85561.html
5) COG AALL0331: Standard Risk B-Precursor Acute Lymphoblastic Leukemia. This study is being conducted in:
- Duarte, CA http://www.centerwatch.com/patient/studies/stu85587.html
6) COG AALL02P2: Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1>18 Months) - A Group-Wide Pilot Study. This study is being conducted in:
- Duarte, CA http://www.centerwatch.com/patient/studies/stu85579.html
7) Defibrotide for Hematopoietic Stem Cell Transplant (SCT) Patients with Severe Hepatic Veno-Occlusive Disease (VOD): A Randomized Phase II Study to Determine the Effective Dose. This study is being conducted in:
- Duarte, CA http://www.centerwatch.com/patient/studies/stu85558.html
8) SWOG S0301: A Phase II Study of Induction with Daunorubicinm Cytarabine, and Cyclosporine all by continuous IV Infusion for Previously Untreated non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older. This study is being conducted in:
- Duarte, CA http://www.centerwatch.com/patient/studies/stu85560.html
9) SWOG S0432: Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Zarnestra, NSC-702818) For Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older. This study is being conducted in:
- Duarte, CA http://www.centerwatch.com/patient/studies/stu85574.html
